Global Pharmaceutical Industry
portes grátis
Global Pharmaceutical Industry
The Demise and the Path to Recovery
Bowditch, Allan; Hoffman, Daniel
Taylor & Francis Ltd
04/2022
130
Mole
Inglês
9780367514235
15 a 20 dias
190
Descrição não disponível.
1. From Family Businesses to Public Darling to the Monster Serving Wall Street;
2. Pharma's Violations and Dirty Tricks;
3. The Economics of the Pharmaceutical Industry;
4. A Somnolent Public Awakens;
5. The Path Toward Reform;
2. Pharma's Violations and Dirty Tricks;
3. The Economics of the Pharmaceutical Industry;
4. A Somnolent Public Awakens;
5. The Path Toward Reform;
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Pharma Companies;Health Technology Assessment;U.S. economy;Drug Prices;social structur;Pharmaceutical Industry;global pharmaceuticals market;Confers;employers' health insurance benefit costs;Key Opinion Leaders;middle-income households;Dirty Tricks;Chronic;Stock Buybacks;CEO;Contemporary Society;Metastatic Renal Cell Cancer;Drug Price Control;Family USA;Net Operating Margin;High Drug Prices;Unintentional Injury Death;Central Social Insurance Medical Council;Gdp Growth;Patented Medicine Prices Review Board;Patient Advocacy Groups;Market Exclusivity;PD-1;State Medicaid Programs;BMS
1. From Family Businesses to Public Darling to the Monster Serving Wall Street;
2. Pharma's Violations and Dirty Tricks;
3. The Economics of the Pharmaceutical Industry;
4. A Somnolent Public Awakens;
5. The Path Toward Reform;
2. Pharma's Violations and Dirty Tricks;
3. The Economics of the Pharmaceutical Industry;
4. A Somnolent Public Awakens;
5. The Path Toward Reform;
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Pharma Companies;Health Technology Assessment;U.S. economy;Drug Prices;social structur;Pharmaceutical Industry;global pharmaceuticals market;Confers;employers' health insurance benefit costs;Key Opinion Leaders;middle-income households;Dirty Tricks;Chronic;Stock Buybacks;CEO;Contemporary Society;Metastatic Renal Cell Cancer;Drug Price Control;Family USA;Net Operating Margin;High Drug Prices;Unintentional Injury Death;Central Social Insurance Medical Council;Gdp Growth;Patented Medicine Prices Review Board;Patient Advocacy Groups;Market Exclusivity;PD-1;State Medicaid Programs;BMS
